Osteoarthritis and cartilage
-
Osteoarthr. Cartil. · Jun 2011
Randomized Controlled Trial Multicenter StudyLong-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.
This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain. ⋯ Repeated injections of tanezumab in patients with moderate to severe knee OA provide continued pain relief and improved function with a low incidence of side effects. Additional studies to define the efficacy and duration of pain reduction and to provide a more complete assessment of long-term safety are warranted.